Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis

JAMA Ophthalmology

Volumn 131, Issue 3, 2013, Pages 310-313

  Ray, Kathryn J ^a   Prajna, Lalitha ^a   Srinivasan, Muthiah ^a   Geetha, Manoharan ^c   Karpagam, Rajarathinam ^c   Glidden, David ^a   Oldenburg, Catherine E ^a   Sun, Catherine Q ^a   McLeod, Stephen D ^a,b   Acharya, Nisha R ^a,b   Lietman, Thomas M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ARAVIND EYE CARE SYSTEM   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACILLUS; BACTERIAL KERATITIS; CONTROLLED STUDY; CORYNEBACTERIUM; DOUBLE BLIND PROCEDURE; ENTEROBACTER; FEMALE; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA; MYCOBACTERIUM; NOCARDIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA; CORNEAL ULCER; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; EYE INFECTIONS, BACTERIAL; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NOCARDIA; NOCARDIA INFECTIONS; PNEUMOCOCCAL INFECTIONS; PREDNISOLONE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUINOLINES; STREPTOCOCCUS PNEUMONIAE;

EID: 84875157404     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.1718     Document Type: Article

References (18)

1. Srinivasan M, Mascarenhas J, Rajaraman R, et al Steroids for Corneal Ulcers Trial Group. Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol. 2012;130(2):143-150.
2. Lalitha P, Srinivasan M, Manikandan P, et al. Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis. Clin Infect Dis. 2012;54(10):1381-1387.
3. Wilhelmus KR. Evaluation and prediction of fluoroquinolone pharmacodynamics in bacterial keratitis. J Ocul Pharmacol Ther. 2003;19(5):493-499.
4. Kaye S, Tuft S, Neal T, et al. Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial keratitis. Invest Ophthalmol Vis Sci. 2010;51(1): 362-368.
5. Chen A, Prajna L, Srinivasan M, et al. Does in vitro susceptibility predict clinical outcome in bacterial keratitis? Am J Ophthalmol. 2008;145(3):409-412.
6. Marangon FB, Miller D, Alfonso EC. Impact of prior therapy on the recovery and frequency of corneal pathogens. Cornea. 2004;23(2):158-164.
7. Fintelmann RE, Hoskins EN, Lietman TM, et al. Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures. Arch Ophthalmol. 2011;129(4):399-402.
8. Srinivasan M, Mascarenhas J, Rajaraman R, et al Steroids for Corneal Ulcers Trial Group. The Steroids for Corneal Ulcers Trial: study design and baseline characteristics. Arch Ophthalmol. 2012;130(2):151-157.
9. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: 10th Informational Supplement (Disk Diffusion). Wayne, PA: National Committee for Clinical Laboratory Standards; 2000. NCCLS document M100-S10 (M2).
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 22nd Informational Supplement. Wayne, PA: Clinical & Laboratory Standards Institute; 2012. Clinical and Laboratory Standards Institute document M100-S22.
11. Andrews JM; BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 6). J Antimicrob Chemother. 2007; 60(1):20-41.
12. Andrews JM, Ashby JP, Jevons GM, Wise R. Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria. J Antimicrob Chemother. 1999;44(6):819-822.
13. King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics. Am Fam Physician. 2000;61(9):2741-2748.
14. El Amari EB, Chamot E, Auckenthaler R, Pechère JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis. 2001;33(11):1859-1864.
15. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol. 2011;129(9):1180-1188.
16. Kim SJ, Toma HS, Midha NK, Cherney EF, Recchia FM, Doherty TJ. Antibiotic resistance of conjunctiva and nasopharynx evaluation study: a prospective study of patients undergoing intravitreal injections. Ophthalmology. 2010;117(12): 2372-2378.
17. Miño de Kaspar H, Koss MJ, He L, Blumenkranz MS, Ta CN. Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol. 2005; 139(4):730-733.
18. Major JC Jr, Engelbert M, Flynn HW Jr, Miller D, Smiddy WE, Davis JL. Staphylococcus aureus endophthalmitis: antibiotic susceptibilities, methicillin resistance, and clinical outcomes. Am J Ophthalmol. 2010;149(2):278-283, e1.